Holen Sie sich die Stockscreener-App
0.0127
0.00%
0.00
Handel nachbörslich:
.01
-0.0027
-21.26%
Schlusskurs vom Vortag:
$0.0127
Offen:
$0.0127
24-Stunden-Volumen:
1,640
Relative Volume:
4.11
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.65M
KGV:
-0.00245
EPS:
-5.1849
Netto-Cashflow:
$-22.84M
1W Leistung:
+0.00%
1M Leistung:
+3.25%
6M Leistung:
-60.92%
1J Leistung:
-99.66%
1-Tages-Spanne:
$0.0127
$0.0127
1-Wochen-Bereich:
$0.0127
$0.0127
52-Wochen-Spanne:
$0.0101
$0.041
Vincerx Pharma Inc Stock (VINC) Company Profile
Firmenname
Vincerx Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare VINC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.0127 | 0 | 0 | -22.65M | -22.84M | -5.1849 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-01 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-13 | Eingeleitet | Laidlaw | Buy |
| 2021-08-25 | Eingeleitet | B. Riley Securities | Buy |
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Drug Transport Company Sued by Insurer Over Destroyed-Cells Case - Bloomberg Law News
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) - Defense World
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Neoleukin Therapeutics (NASDAQ:NLTX) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR - GlobeNewswire
Vincerx Pharma, Inc. Announces Adjournment of Special MeetingWill Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal - Yahoo Finance
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Global Digital Holdings Inc. cancelled the acquisition of Vincerx Pharma, Inc. in a reverse merger transaction. - marketscreener.com
VINC: Vincerx Pharma to dissolve, with minimal or no distributions expected for stockholders - TradingView
VINC Stock Price, News & Analysis | Vincerx Pharma - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView — Track All Markets
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com Australia
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - GlobeNewswire
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind downSan Francisco Business Times - The Business Journals
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - GlobeNewswire
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewswire
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Stocktwits
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Pharma (NASDAQ: VINCU)Share Price - intelligentinvestor.com.au
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Pre-market Movers: NKGN, CELZ, AFMD, EVA, VINC.... - RTTNews
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 - Yahoo Finance
Vincerx Pharma Announces FDA Clearance of IND for VIP943 - GlobeNewswire
Andrew I Mcdonald Net Worth (2025) - GuruFocus
Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.77%
Kapitalisierung:
|
Volumen (24h):